| Filed On | Filing |
|---|---|
| 13 Nov 2026 | 10-Q |
| 13 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 03 Nov 2026 | SCHEDULE 13G |
| 14 Aug 2026 | 10-Q |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition
Continued advancing IND-enabling studies supporting the planned submission of an Investigational New Drug (IND) application for EB-003 and expected initiation of Phase 1 clinical trial |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 09 Jun 2026 |
8-K: Other Events
Registration Statement on Form S-3 Enveric Biosciences, Inc. |
| 09 Jun 2026 | 424B5 |
| 09 Jun 2026 |
8-K: Regulation FD Disclosure
Enveric Biosciences, Inc. (the “Company”) has prepared presentation materials (the “Investor Presentation”) that management intends to release on its website on or about June 8, 2026. From time to time thereafter, the Company may use the... |
| 03 Jun 2026 |
Form 4: Coveney Kevin Michael, Chief Financial Officer
Received 133,333 shares as a grant or award |
| 03 Jun 2026 |
Form 4: Tucker Joseph Edward, Director
Received 201,124 shares as a grant or award |
| 03 Jun 2026 |
Form 4: Pasqualone Frank, Director
Received 18,518 shares as a grant or award |
| 03 Jun 2026 |
Form 4: Webb Michael D, Director
Received 18,518 shares as a grant or award |
| 03 Jun 2026 |
Form 4: Schabacker Marcus, Director
Received 18,518 shares as a grant or award |
| 03 Jun 2026 |
Form 4: Kegler George A., Director
Received 18,518 shares as a grant or award |
| 03 Jun 2026 |
Form 4: DeWitt Sheila, Director
Received 18,518 shares as a grant or award |
| 03 Jun 2026 |
Form 4: Facchini Peter J., Chief Innovation Officer
Received 25,000 shares as a grant or award |
| 01 Jun 2026 | S-8 |
Loading...